Ads
related to: side effects of pomalyst for multiple myeloma
Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [7] Pomalidomide was approved for medical use in the United States in February 2013, [10] and in the European Union in August 2013. [8] It is available as a generic ...
This disrupts the positive feedback loop between the two growth factors, possibly causing both multiple birth defects and anti-myeloma effects. Findings also support the hypothesis that an increase in the expression of cereblon is an essential element of the anti-myeloma effect of both lenalidomide and pomalidomide. [29]
After years of clinical studies, the Food and Drug Administration approved pomalidomide, now branded as Pomalyst, for treatment of relapsed or refractory multiple myeloma on Feb. 8, 2013.
The U.S. FDA in April approved two cell therapies - J&J's Carvykti, and Bristol Myers' Abecma - as earlier lines of treatment in less severe multiple myeloma. Eye-related side effects led to a 9% ...
Dimopoulos MA, Hungria VT, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. (October 2023). "Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study". The Lancet. Haematology.
Oral Anti-Cancer Therapy Pomalidomide Now Approved by European Commission as Treatment for Patients with Relapsed/Refractory Multiple Myeloma - a Rare Form of Blood Cancer BOUDRY, Switzerland ...
Ads
related to: side effects of pomalyst for multiple myeloma